Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $4.3 billion for Q2 2026.

• In Q2 2026, Revenue rose 16.73% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $15.5 billion (up 9.29% YoY), while the FY2025 annual figure was $14.3 billion, up 0.99% from the prior year.
• Revenue for Q2 2026 stood at $4.3 billion, up from $3.6 billion in the prior quarter.
• The five-year high for Revenue was $4.3 billion in Q2 2026, with the low at $50.0 million in Q1 2022.
• The 5-year median for Revenue is $3.4 billion (2023), against an average of $3.1 billion.
• The sharpest annual moves came in 2022 and 2023: Revenue sank 98.02% in 2022, then soared 6224.2% in 2023.
• Regeneron Pharmaceuticals' Revenue stood at $100.0 million in 2022, then jumped by 3334.3% to $3.4 billion in 2023, then rose by 10.33% to $3.8 billion in 2024, then rose by 2.51% to $3.9 billion in 2025, then grew by 10.46% to $4.3 billion in 2026.
• Business Quant data shows REGN's Revenue at $4.3 billion in Q2 2026, $3.6 billion in Q1 2026, and $3.9 billion in Q4 2025.